What are the management and treatment options for a patient with a positive RET (rearranged during transfection) sequencing and deletion/duplication result, indicating a high risk for multiple endocrine neoplasia type 2 (MEN2)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: January 25, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Management of Positive RET Mutation in MEN2

Patients with a positive RET mutation require risk-stratified prophylactic total thyroidectomy, with the timing determined by the specific codon mutation identified, and must undergo preoperative screening to exclude pheochromocytoma before any thyroid surgery. 1

Immediate Preoperative Requirements

Before proceeding with any surgical intervention, you must exclude pheochromocytoma, as it occurs in approximately 50% of MEN2A and MEN2B patients and must be treated first to avoid hypertensive crisis during thyroid surgery. 2, 1 If pheochromocytoma is present, perform laparoscopic adrenalectomy with α-adrenergic blockade (phenoxybenzamine) or α-methyltyrosine, followed by forced hydration and α-blockade to prevent hypotension after tumor removal. 2

Additionally, screen for hyperparathyroidism in MEN2A patients (occurs in 20-30% of cases, particularly with codon 634 mutations) by measuring serum intact parathyroid hormone and calcium levels. 2, 1

Risk-Stratified Surgical Timing Based on RET Codon

The specific RET mutation dictates both the aggressiveness of medullary thyroid carcinoma (MTC) and the timing of prophylactic surgery:

Highest Risk (Level D) Mutations

  • Codons 883,918,922 (MEN2B or compound heterozygous mutations V804M + E805K, V804M + Y806C, or V804M + S904C): Perform total thyroidectomy within the first year of life or at diagnosis. 2, 1 These mutations carry 100% lifetime risk of MTC with early aggressive behavior and distant metastatic spread. 2, 3

High Risk (Level B) Mutations

  • Codons 609,611,618,620,630,634: Perform prophylactic total thyroidectomy by age 5 years or when mutation is identified (if diagnosed at older age). 2 Codon 634 mutations are the most common RET mutations in MEN2A. 2, 1

Moderate Risk (Level A) Mutations

  • Codons 768,790,791,804,891: These mutations have lower lethality and later onset of MTC development. 2 You may defer total thyroidectomy beyond age 5 if all of the following criteria are met:
    • Annual basal calcitonin testing remains normal
    • Annual neck ultrasound is unremarkable
    • No family history of aggressive MTC
    • Family agrees to surveillance approach 2

Surgical Approach

Perform total thyroidectomy with bilateral central neck dissection (level VI) as the standard procedure. 2, 4 The extent of lymph node dissection depends on preoperative findings:

  • For prophylactic surgery in MEN2A: Add therapeutic ipsilateral or bilateral central neck dissection (level VI) if elevated calcitonin/CEA or ultrasound shows thyroid or nodal abnormality. 2

  • For MEN2B: Consider bilateral central neck dissection (level VI) for all patients. 2

  • For established MTC ≥1 cm or central node metastases: Consider more extensive lymph node dissection (levels II-V). 2

Refer patients to surgeons experienced in pediatric thyroid surgery, as this minimizes complications including hypoparathyroidism (0.5-3% permanent rate) and recurrent laryngeal nerve injury (1.9-3% rate). 2, 4

Management of Concurrent Hyperparathyroidism

If multiglandular parathyroid hyperplasia is present during surgery, leave or autotransplant the equivalent mass of one normal parathyroid gland. 2 Consider cryopreservation of resected parathyroid tissue for potential future implantation if iatrogenic hypoparathyroidism develops. 2

Postoperative Management

Initiate levothyroxine therapy immediately after surgery to maintain TSH in the normal range (not suppressed, as C cells lack TSH receptors). 2

At 2-3 months postoperatively, measure basal calcitonin and CEA:

  • Undetectable basal calcitonin: Continue observation with calcitonin/CEA every 6-12 months. 2 The likelihood of significant residual disease is very low. 2
  • Detectable calcitonin or elevated CEA: Obtain contrast-enhanced CT or MRI of neck, chest, abdomen with liver protocol if calcitonin >150 pg/mL. 2

For MEN2A/2B patients, perform annual lifelong screening for pheochromocytoma and hyperparathyroidism (MEN2A only). 2, 1

Genetic Testing and Family Screening

All patients with newly diagnosed MTC, even those appearing to have sporadic disease, should undergo RET genetic testing, as approximately 6% of clinically sporadic MTC cases carry germline RET mutations. 2, 1 The de novo mutation rate is 9% in MEN2A and up to 50% in MEN2B, making genetic testing essential even without family history. 1

Critical Pitfalls to Avoid

  • Never proceed with thyroid surgery before excluding and treating pheochromocytoma—this can cause fatal hypertensive crisis. 2
  • Do not use TSH suppression therapy postoperatively, as MTC cells lack TSH receptors; maintain TSH in normal range. 2
  • Do not delay surgery in highest-risk mutations (codons 883,918,922) beyond the first year of life. 2, 1
  • Prophylactic thyroidectomy achieves 89% surgical cure rate in asymptomatic carriers versus only 25% in symptomatic patients with palpable nodules. 1

References

Guideline

Management of Multiple Endocrine Neoplasia Type 2 (MEN2)

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Guideline

Indications for Total Thyroidectomy

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.